Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralatrexate and Romidepsin in Peripheral T-cell Lymphoma
NCT01947140Phase 2Terminated
- Start
- Sep 2013
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pralatrexate and romidepsin in lymphoma and multiple myeloma (MM) (3 arms). Primary endpoints: Maximum Tolerated Dose at 1.5 years and Overall Response Rate at 3 years. Started Sep 2013; status: terminated.
02
Drugs
pralatrexateromidepsin
03
Conditions
lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT01947140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01947140.